[{"id":"63ba93fd-a0f6-4865-ad2d-03267b454c0a","acronym":"S1802","url":"https://clinicaltrials.gov/study/NCT03678025","created_at":"2021-07-05T17:17:10.086Z","updated_at":"2025-02-25T16:31:34.107Z","phase":"Phase 3","brief_title":"Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer","source_id_and_acronym":"NCT03678025 - S1802","lead_sponsor":"SWOG Cancer Research Network","biomarkers":" SYP","pipe":"","alterations":" ","tags":["SYP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • abiraterone acetate • prednisone • Eligard (leuprolide acetate) • bicalutamide • triptorelin • goserelin acetate • flutamide • nilutamide • Firmagon (degarelix) • Viadur (leuprorelin implant)"],"overall_status":"Recruiting","enrollment":" Enrollment 1273","initiation":"Initiation: 09/24/2018","start_date":" 09/24/2018","primary_txt":" Primary completion: 04/01/2028","primary_completion_date":" 04/01/2028","study_txt":" Completion: 10/01/2031","study_completion_date":" 10/01/2031","last_update_posted":"2024-08-16"},{"id":"a49db657-c86f-4248-a70f-ffa82ef7bb32","acronym":"","url":"https://clinicaltrials.gov/study/NCT05110170","created_at":"2021-11-05T12:53:26.217Z","updated_at":"2024-07-02T16:35:47.867Z","phase":"Phase 3","brief_title":"Efficacy and Safety of LY01005 in Patients With Breast Cancer Compared to ZOLADEX®","source_id_and_acronym":"NCT05110170","lead_sponsor":"Luye Pharma Group Ltd.","biomarkers":" ER","pipe":"","alterations":" ","tags":["ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • goserelin acetate • Baituowei (goserelin acetate sustained-release microspheres for injection)"],"overall_status":"Completed","enrollment":" Enrollment 188","initiation":"Initiation: 10/15/2020","start_date":" 10/15/2020","primary_txt":" Primary completion: 04/05/2022","primary_completion_date":" 04/05/2022","study_txt":" Completion: 06/24/2022","study_completion_date":" 06/24/2022","last_update_posted":"2023-05-16"}]